Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A third of patients treated with Opdivo plus Yervoy experienced complete or partial tumor remission.
“As far as we know, immunotherapy on its own would not make patients more susceptible to COVID-19."
A triple regimen of Opdivo, Yervoy and Cabometyx showed good antitumor activity, but severe side effects were common.
The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.
Longer-term follow-up shows improved overall survival with Keytruda or Opdivo.
New site-agnostic therapies highlight the importance of genetic testing.
Checkpoint inhibitor combination led to higher response rates and longer survival than Opdivo alone.
The findings could help identify patients who might benefit from combination therapy with a checkpoint blocker and another inhibitor.
The investigational machine has an 85% accuracy rate.
Immunotherapy led to fewer side effects and better quality of life than standard-of-care therapy.
NKTR-214 plus Opdivo has been granted an FDA breakthrough therapy designation for advanced melanoma.
Phase III study misses statistical threshold, but the immunotherapy appears to show some benefit.
Could new cancer drugs restore immune responses against HIV?
Keytruda showed modest benefits for people with this difficult-to-treat cancer, and combining Opdivo with Yervoy improved outcomes.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.